The FDA has expressed concern with direct-to-consumer marketing across the pharmaceutical industry and an intent to more aggressively enforce laws that require fair balance between a products risks and benefits
The goal is not just weight loss but lifelong healthy weight management
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Center for Complementary and Integrative Health (NCCIH) both acknowledge the evidence base for GLP-1 receptor agonists in obesity medicine as part of the broader federal research and clinical guidance infrastructure
Meanwhile, its interaction with nitrate ester drugs (such as nitroglycerin) may cause fatal hypotension, and when used in combination with CYP3A4 inhibitors (such as ketoconazole and rifampicin), dosage adjustment is required, increasing the complexity of medication management
Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP, et al